| HOME >> MEDICINE >> TECHNOLOGY |
A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC)Dr. Hope Rugo, UCSF Comprehensive Cancer Center, San Francisco, CA, abstract # 1042, poster discussion, Tuesday, June 3, 11:00 am - 12:00 pm, E Hall 354a; (poster presentation 8:00 am - 12:00 pm, E Hall 450B)
Clinical activity of lapatinib monotherapy in patients with HER2+ relapsed/refractory inflammatory breast cancer (IBC): final results of the expanded HER2+ cohort in EGF103009 [Phase II]Dr. Bella Kaufman, The Chaim Sheba Medical Center, Tel Hashomer, Israel, abstract # 636, poster presentation, Monday, June 02, 2008, 2 pm - 6 pm, S-Hall A1
Melanoma
Phase II trial of elesclomol* (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): Subgroup analysis by prior chemotherapyDr. David Lawson, Emory University, abstract # 9036, poster presentation, Saturday, May 31, 2008, 2 pm - 6 pm, S-Hall A1
Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC Melanoma Group (16032-18031)Dr. Wim Kruit, Erasmus Medical Center, Rotterdam, Netherlands, abstract # 9065, poster presentation, Saturday, May 31, 2008, 2 pm - 6 pm, S-Hall A1
Chemotherapy-Induced Nausea and Vomiting (CINV)
Phase III results of a novel neurokinin-1 (NK-1) receptor antagonist,
casopitant: single oral and 3-day oral dosing regimens for
chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving
moderately emetogenic chemotherapy (MEC)Dr. Steven Grunberg, Vermont Cancer
Center at University of Vermont and Fletcher Allen Health Care, abstract #
9540, poster discussion, Frida
'/>"/>
| SOURCE GlaxoSmithKline Copyright©2008 PR Newswire. All rights reserved |